The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global PD-1 Inhibitor Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The PD-1 Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global PD-1 Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Melanoma accounting for % of the PD-1 Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Pembrolizumab segment is altered to a % CAGR between 2022 and 2028.
Global key companies of PD-1 Inhibitor include Merck, Novartis, Onxeo, Sumitomo Dainippon Pharma, and Taiwan Liposome Company, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
PD-1 Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab
Avelumab
Other
Market segment by Application, can be divided into
Melanoma
Non-small Cell Lung Cancer (NSCLC)
Urothelial Carcinoma
Classical Hodgkin Lymphoma
Renal Cell Carcinoma
Other
Market segment by players, this report covers
Merck
Novartis
Onxeo
Sumitomo Dainippon Pharma
Taiwan Liposome Company
Tiziana Life Sciences
Genentech (Roche)
AstraZeneca
Pfizer
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe PD-1 Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of PD-1 Inhibitor, with revenue, gross margin and global market share of PD-1 Inhibitor from 2019 to 2022.
Chapter 3, the PD-1 Inhibitor competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and PD-1 Inhibitor market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe PD-1 Inhibitor research findings and conclusion, appendix and data source.
Geographical Area
Global
The PD-1 Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global PD-1 Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Melanoma accounting for % of the PD-1 Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Pembrolizumab segment is altered to a % CAGR between 2022 and 2028.
Global key companies of PD-1 Inhibitor include Merck, Novartis, Onxeo, Sumitomo Dainippon Pharma, and Taiwan Liposome Company, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
PD-1 Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab
Avelumab
Other
Market segment by Application, can be divided into
Melanoma
Non-small Cell Lung Cancer (NSCLC)
Urothelial Carcinoma
Classical Hodgkin Lymphoma
Renal Cell Carcinoma
Other
Market segment by players, this report covers
Merck
Novartis
Onxeo
Sumitomo Dainippon Pharma
Taiwan Liposome Company
Tiziana Life Sciences
Genentech (Roche)
AstraZeneca
Pfizer
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe PD-1 Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of PD-1 Inhibitor, with revenue, gross margin and global market share of PD-1 Inhibitor from 2019 to 2022.
Chapter 3, the PD-1 Inhibitor competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and PD-1 Inhibitor market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe PD-1 Inhibitor research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of PD-1 Inhibitor
1.2 Classification of PD-1 Inhibitor by Type
1.2.1 Overview: Global PD-1 Inhibitor Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global PD-1 Inhibitor Revenue Market Share by Type in 2021
1.2.3 Pembrolizumab
1.2.4 Nivolumab
1.2.5 Atezolizumab
1.2.6 Durvalumab
1.2.7 Avelumab
1.2.8 Other
1.3 Global PD-1 Inhibitor Market by Application
1.3.1 Overview: Global PD-1 Inhibitor Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Melanoma
1.3.3 Non-small Cell Lung Cancer (NSCLC)
1.3.4 Urothelial Carcinoma
1.3.5 Classical Hodgkin Lymphoma
1.3.6 Renal Cell Carcinoma
1.3.7 Other
1.4 Global PD-1 Inhibitor Market Size & Forecast
1.5 Global PD-1 Inhibitor Market Size and Forecast by Region
1.5.1 Global PD-1 Inhibitor Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global PD-1 Inhibitor Market Size by Region, (2017-2022)
1.5.3 North America PD-1 Inhibitor Market Size and Prospect (2017-2028)
1.5.4 Europe PD-1 Inhibitor Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific PD-1 Inhibitor Market Size and Prospect (2017-2028)
1.5.6 South America PD-1 Inhibitor Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa PD-1 Inhibitor Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 PD-1 Inhibitor Market Drivers
1.6.2 PD-1 Inhibitor Market Restraints
1.6.3 PD-1 Inhibitor Trends Analysis
2 Company Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck PD-1 Inhibitor Product and Solutions
2.1.4 Merck PD-1 Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Merck Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis PD-1 Inhibitor Product and Solutions
2.2.4 Novartis PD-1 Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Onxeo
2.3.1 Onxeo Details
2.3.2 Onxeo Major Business
2.3.3 Onxeo PD-1 Inhibitor Product and Solutions
2.3.4 Onxeo PD-1 Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Onxeo Recent Developments and Future Plans
2.4 Sumitomo Dainippon Pharma
2.4.1 Sumitomo Dainippon Pharma Details
2.4.2 Sumitomo Dainippon Pharma Major Business
2.4.3 Sumitomo Dainippon Pharma PD-1 Inhibitor Product and Solutions
2.4.4 Sumitomo Dainippon Pharma PD-1 Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Sumitomo Dainippon Pharma Recent Developments and Future Plans
2.5 Taiwan Liposome Company
2.5.1 Taiwan Liposome Company Details
2.5.2 Taiwan Liposome Company Major Business
2.5.3 Taiwan Liposome Company PD-1 Inhibitor Product and Solutions
2.5.4 Taiwan Liposome Company PD-1 Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Taiwan Liposome Company Recent Developments and Future Plans
2.6 Tiziana Life Sciences
2.6.1 Tiziana Life Sciences Details
2.6.2 Tiziana Life Sciences Major Business
2.6.3 Tiziana Life Sciences PD-1 Inhibitor Product and Solutions
2.6.4 Tiziana Life Sciences PD-1 Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Tiziana Life Sciences Recent Developments and Future Plans
2.7 Genentech (Roche)
2.7.1 Genentech (Roche) Details
2.7.2 Genentech (Roche) Major Business
2.7.3 Genentech (Roche) PD-1 Inhibitor Product and Solutions
2.7.4 Genentech (Roche) PD-1 Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Genentech (Roche) Recent Developments and Future Plans
2.8 AstraZeneca
2.8.1 AstraZeneca Details
2.8.2 AstraZeneca Major Business
2.8.3 AstraZeneca PD-1 Inhibitor Product and Solutions
2.8.4 AstraZeneca PD-1 Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 AstraZeneca Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer PD-1 Inhibitor Product and Solutions
2.9.4 Pfizer PD-1 Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Pfizer Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global PD-1 Inhibitor Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 PD-1 Inhibitor Players Market Share in 2021
3.2.2 Top 10 PD-1 Inhibitor Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 PD-1 Inhibitor Players Head Office, Products and Services Provided
3.4 PD-1 Inhibitor Mergers & Acquisitions
3.5 PD-1 Inhibitor New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global PD-1 Inhibitor Revenue and Market Share by Type (2017-2022)
4.2 Global PD-1 Inhibitor Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global PD-1 Inhibitor Revenue Market Share by Application (2017-2022)
5.2 Global PD-1 Inhibitor Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America PD-1 Inhibitor Revenue by Type (2017-2028)
6.2 North America PD-1 Inhibitor Revenue by Application (2017-2028)
6.3 North America PD-1 Inhibitor Market Size by Country
6.3.1 North America PD-1 Inhibitor Revenue by Country (2017-2028)
6.3.2 United States PD-1 Inhibitor Market Size and Forecast (2017-2028)
6.3.3 Canada PD-1 Inhibitor Market Size and Forecast (2017-2028)
6.3.4 Mexico PD-1 Inhibitor Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe PD-1 Inhibitor Revenue by Type (2017-2028)
7.2 Europe PD-1 Inhibitor Revenue by Application (2017-2028)
7.3 Europe PD-1 Inhibitor Market Size by Country
7.3.1 Europe PD-1 Inhibitor Revenue by Country (2017-2028)
7.3.2 Germany PD-1 Inhibitor Market Size and Forecast (2017-2028)
7.3.3 France PD-1 Inhibitor Market Size and Forecast (2017-2028)
7.3.4 United Kingdom PD-1 Inhibitor Market Size and Forecast (2017-2028)
7.3.5 Russia PD-1 Inhibitor Market Size and Forecast (2017-2028)
7.3.6 Italy PD-1 Inhibitor Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific PD-1 Inhibitor Revenue by Type (2017-2028)
8.2 Asia-Pacific PD-1 Inhibitor Revenue by Application (2017-2028)
8.3 Asia-Pacific PD-1 Inhibitor Market Size by Region
8.3.1 Asia-Pacific PD-1 Inhibitor Revenue by Region (2017-2028)
8.3.2 China PD-1 Inhibitor Market Size and Forecast (2017-2028)
8.3.3 Japan PD-1 Inhibitor Market Size and Forecast (2017-2028)
8.3.4 South Korea PD-1 Inhibitor Market Size and Forecast (2017-2028)
8.3.5 India PD-1 Inhibitor Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia PD-1 Inhibitor Market Size and Forecast (2017-2028)
8.3.7 Australia PD-1 Inhibitor Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America PD-1 Inhibitor Revenue by Type (2017-2028)
9.2 South America PD-1 Inhibitor Revenue by Application (2017-2028)
9.3 South America PD-1 Inhibitor Market Size by Country
9.3.1 South America PD-1 Inhibitor Revenue by Country (2017-2028)
9.3.2 Brazil PD-1 Inhibitor Market Size and Forecast (2017-2028)
9.3.3 Argentina PD-1 Inhibitor Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa PD-1 Inhibitor Revenue by Type (2017-2028)
10.2 Middle East & Africa PD-1 Inhibitor Revenue by Application (2017-2028)
10.3 Middle East & Africa PD-1 Inhibitor Market Size by Country
10.3.1 Middle East & Africa PD-1 Inhibitor Revenue by Country (2017-2028)
10.3.2 Turkey PD-1 Inhibitor Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia PD-1 Inhibitor Market Size and Forecast (2017-2028)
10.3.4 UAE PD-1 Inhibitor Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global PD-1 Inhibitor Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global PD-1 Inhibitor Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market PD-1 Inhibitor Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global PD-1 Inhibitor Revenue (USD Million) by Region (2017-2022)
Table 5. Global PD-1 Inhibitor Revenue Market Share by Region (2023-2028)
Table 6. Merck Corporate Information, Head Office, and Major Competitors
Table 7. Merck Major Business
Table 8. Merck PD-1 Inhibitor Product and Solutions
Table 9. Merck PD-1 Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Novartis Corporate Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis PD-1 Inhibitor Product and Solutions
Table 13. Novartis PD-1 Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Onxeo Corporate Information, Head Office, and Major Competitors
Table 15. Onxeo Major Business
Table 16. Onxeo PD-1 Inhibitor Product and Solutions
Table 17. Onxeo PD-1 Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Sumitomo Dainippon Pharma Corporate Information, Head Office, and Major Competitors
Table 19. Sumitomo Dainippon Pharma Major Business
Table 20. Sumitomo Dainippon Pharma PD-1 Inhibitor Product and Solutions
Table 21. Sumitomo Dainippon Pharma PD-1 Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Taiwan Liposome Company Corporate Information, Head Office, and Major Competitors
Table 23. Taiwan Liposome Company Major Business
Table 24. Taiwan Liposome Company PD-1 Inhibitor Product and Solutions
Table 25. Taiwan Liposome Company PD-1 Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Tiziana Life Sciences Corporate Information, Head Office, and Major Competitors
Table 27. Tiziana Life Sciences Major Business
Table 28. Tiziana Life Sciences PD-1 Inhibitor Product and Solutions
Table 29. Tiziana Life Sciences PD-1 Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Genentech (Roche) Corporate Information, Head Office, and Major Competitors
Table 31. Genentech (Roche) Major Business
Table 32. Genentech (Roche) PD-1 Inhibitor Product and Solutions
Table 33. Genentech (Roche) PD-1 Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 35. AstraZeneca Major Business
Table 36. AstraZeneca PD-1 Inhibitor Product and Solutions
Table 37. AstraZeneca PD-1 Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Pfizer Corporate Information, Head Office, and Major Competitors
Table 39. Pfizer Major Business
Table 40. Pfizer PD-1 Inhibitor Product and Solutions
Table 41. Pfizer PD-1 Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global PD-1 Inhibitor Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global PD-1 Inhibitor Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of PD-1 Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. PD-1 Inhibitor Players Head Office, Products and Services Provided
Table 46. PD-1 Inhibitor Mergers & Acquisitions in the Past Five Years
Table 47. PD-1 Inhibitor New Entrants and Expansion Plans
Table 48. Global PD-1 Inhibitor Revenue (USD Million) by Type (2017-2022)
Table 49. Global PD-1 Inhibitor Revenue Share by Type (2017-2022)
Table 50. Global PD-1 Inhibitor Revenue Forecast by Type (2023-2028)
Table 51. Global PD-1 Inhibitor Revenue by Application (2017-2022)
Table 52. Global PD-1 Inhibitor Revenue Forecast by Application (2023-2028)
Table 53. North America PD-1 Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 54. North America PD-1 Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 55. North America PD-1 Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 56. North America PD-1 Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 57. North America PD-1 Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 58. North America PD-1 Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe PD-1 Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe PD-1 Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe PD-1 Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe PD-1 Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe PD-1 Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe PD-1 Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific PD-1 Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific PD-1 Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific PD-1 Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific PD-1 Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific PD-1 Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific PD-1 Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 71. South America PD-1 Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 72. South America PD-1 Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 73. South America PD-1 Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 74. South America PD-1 Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 75. South America PD-1 Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 76. South America PD-1 Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa PD-1 Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa PD-1 Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa PD-1 Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa PD-1 Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa PD-1 Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa PD-1 Inhibitor Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. PD-1 Inhibitor Picture
Figure 2. Global PD-1 Inhibitor Revenue Market Share by Type in 2021
Figure 3. Pembrolizumab
Figure 4. Nivolumab
Figure 5. Atezolizumab
Figure 6. Durvalumab
Figure 7. Avelumab
Figure 8. Other
Figure 9. PD-1 Inhibitor Revenue Market Share by Application in 2021
Figure 10. Melanoma Picture
Figure 11. Non-small Cell Lung Cancer (NSCLC) Picture
Figure 12. Urothelial Carcinoma Picture
Figure 13. Classical Hodgkin Lymphoma Picture
Figure 14. Renal Cell Carcinoma Picture
Figure 15. Other Picture
Figure 16. Global PD-1 Inhibitor Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 17. Global PD-1 Inhibitor Revenue and Forecast (2017-2028) & (USD Million)
Figure 18. Global PD-1 Inhibitor Revenue Market Share by Region (2017-2028)
Figure 19. Global PD-1 Inhibitor Revenue Market Share by Region in 2021
Figure 20. North America PD-1 Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Europe PD-1 Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Asia-Pacific PD-1 Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. South America PD-1 Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)
Figure 24. Middle East and Africa PD-1 Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)
Figure 25. PD-1 Inhibitor Market Drivers
Figure 26. PD-1 Inhibitor Market Restraints
Figure 27. PD-1 Inhibitor Market Trends
Figure 28. Merck Recent Developments and Future Plans
Figure 29. Novartis Recent Developments and Future Plans
Figure 30. Onxeo Recent Developments and Future Plans
Figure 31. Sumitomo Dainippon Pharma Recent Developments and Future Plans
Figure 32. Taiwan Liposome Company Recent Developments and Future Plans
Figure 33. Tiziana Life Sciences Recent Developments and Future Plans
Figure 34. Genentech (Roche) Recent Developments and Future Plans
Figure 35. AstraZeneca Recent Developments and Future Plans
Figure 36. Pfizer Recent Developments and Future Plans
Figure 37. Global PD-1 Inhibitor Revenue Share by Players in 2021
Figure 38. PD-1 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 39. Global Top 3 Players PD-1 Inhibitor Revenue Market Share in 2021
Figure 40. Global Top 10 Players PD-1 Inhibitor Revenue Market Share in 2021
Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 42. Global PD-1 Inhibitor Revenue Share by Type in 2021
Figure 43. Global PD-1 Inhibitor Market Share Forecast by Type (2023-2028)
Figure 44. Global PD-1 Inhibitor Revenue Share by Application in 2021
Figure 45. Global PD-1 Inhibitor Market Share Forecast by Application (2023-2028)
Figure 46. North America PD-1 Inhibitor Sales Market Share by Type (2017-2028)
Figure 47. North America PD-1 Inhibitor Sales Market Share by Application (2017-2028)
Figure 48. North America PD-1 Inhibitor Revenue Market Share by Country (2017-2028)
Figure 49. United States PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Canada PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Mexico PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Europe PD-1 Inhibitor Sales Market Share by Type (2017-2028)
Figure 53. Europe PD-1 Inhibitor Sales Market Share by Application (2017-2028)
Figure 54. Europe PD-1 Inhibitor Revenue Market Share by Country (2017-2028)
Figure 55. Germany PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. France PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. United Kingdom PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Russia PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Italy PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Asia-Pacific PD-1 Inhibitor Sales Market Share by Type (2017-2028)
Figure 61. Asia-Pacific PD-1 Inhibitor Sales Market Share by Application (2017-2028)
Figure 62. Asia-Pacific PD-1 Inhibitor Revenue Market Share by Region (2017-2028)
Figure 63. China PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Japan PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South Korea PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. India PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Southeast Asia PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Australia PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. South America PD-1 Inhibitor Sales Market Share by Type (2017-2028)
Figure 70. South America PD-1 Inhibitor Sales Market Share by Application (2017-2028)
Figure 71. South America PD-1 Inhibitor Revenue Market Share by Country (2017-2028)
Figure 72. Brazil PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Argentina PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Middle East and Africa PD-1 Inhibitor Sales Market Share by Type (2017-2028)
Figure 75. Middle East and Africa PD-1 Inhibitor Sales Market Share by Application (2017-2028)
Figure 76. Middle East and Africa PD-1 Inhibitor Revenue Market Share by Country (2017-2028)
Figure 77. Turkey PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. UAE PD-1 Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Methodology
Figure 81. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
